HCWB Stock Forecast 2025-2026
Distance to HCWB Price Targets
HCWB Price Momentum
10 Quality Stocks Worth Considering Now
Researching HCW Biologics (HCWB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on HCWB and similar high-potential opportunities.
Latest HCWB Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, HCWB has a bullish consensus with a median price target of $120.00 (ranging from $120.00 to $120.00). Currently trading at $7.05, the median forecast implies a 1,602.1% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HCWB Analyst Ratings
HCWB Price Target Range
Latest HCWB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HCWB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 1, 2023 | EF Hutton | Tony Butler | Buy | Assumes | $9.00 |
| Apr 19, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Mar 30, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Mar 23, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Nov 8, 2022 | JonesTrading | Soumit Roy | Buy | Initiates | $8.00 |
| Mar 24, 2022 | Maxim Group | Michael Okunewitch | Buy | Initiates | $4.00 |
| Nov 19, 2021 | EF Hutton | Buy | Initiates | $0.00 |
HCW Biologics Inc. (HCWB) Competitors
The following stocks are similar to HCW Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HCW Biologics Inc. (HCWB) Financial Data
HCW Biologics Inc. has a market capitalization of $7.92M with a P/E ratio of -9.2x. The company generates $2.57M in trailing twelve-month revenue with a 37.4% profit margin.
Revenue growth is -70.2% quarter-over-quarter, while maintaining an operating margin of -1,129.6% and return on equity of -897.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
HCW Biologics Inc. (HCWB) Business Model
About HCW Biologics Inc.
Develops immunotherapies for age-related diseases and cancer.
The company leverages proprietary platform technologies to develop biologics that target senescent cells, which are implicated in chronic diseases. HCW Biologics generates revenue through the discovery and development of innovative therapies that address significant healthcare needs, particularly in oncology and regenerative medicine.
HCW Biologics is positioned at the intersection of biotechnology and therapeutic innovation, focusing on improving the quality of life for aging populations. Its research initiatives aim to create novel treatments that can significantly impact the pharmaceutical landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
36
CEO
Dr. Hing C. Wong Ph.D.
Country
United States
IPO Year
2021
Website
www.hcwbiologics.comHCW Biologics Inc. (HCWB) Latest News & Analysis
HCW Biologics Inc. (NASDAQ: HCWB) will implement a 1-for-40 reverse stock split effective April 11, 2025, with trading on a split-adjusted basis commencing the same day.
A 1-for-40 reverse stock split often signals a company’s attempt to boost its stock price and maintain listing requirements, which can affect liquidity and investor perception of financial health.
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
21 days agoHCW Biologics Inc. (NASDAQ: HCWB) reported its financial results for Q4 and FY 2024, focusing on immunotherapies aimed at combating inflammation and age-related diseases.
HCW Biologics' financial results and business updates signal its progress in immunotherapy, impacting its stock performance and investor confidence in its growth potential.
HCW Biologics Inc. (Nasdaq: HCWB) received an extension from the Nasdaq Hearings Panel to regain compliance with listing rules, as reported on March 3, 2025.
HCW Biologics receiving a compliance extension from Nasdaq can stabilize its stock price, providing a potential opportunity for recovery and growth in investor confidence.
HCW Biologics Inc. (NASDAQ: HCWB) has received FDA clearance for its IND to start a Phase 1 trial of HCW9302 for treating moderate-to-severe alopecia areata, an autoimmune disease.
FDA clearance for HCWB's IND to trial HCW9302 in alopecia areata opens growth potential, as it targets an unmet medical need, potentially driving stock value and attracting investor interest.
HCW Biologics (NASDAQ: HCWB) announced a focus on developing novel immunotherapies targeting chronic inflammation to enhance healthspan, as of January 15, 2025.
HCW Biologics' focus on novel immunotherapies could lead to significant advancements in treating chronic diseases, influencing investor confidence and stock performance.
HCW Biologics Inc. (NASDAQ: HCWB) received a notice from Nasdaq regarding non-compliance with listing requirements and plans to appeal the decision.
The notice of potential delisting signals financial instability, which could lead to a decline in stock value and investor confidence in HCW Biologics.
Frequently Asked Questions About HCWB Stock
What is HCW Biologics Inc.'s (HCWB) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, HCW Biologics Inc. (HCWB) has a median price target of $120.00. The highest price target is $120.00 and the lowest is $120.00.
Is HCWB stock a good investment in 2025?
According to current analyst ratings, HCWB has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HCWB stock?
Wall Street analysts predict HCWB stock could reach $120.00 in the next 12 months. This represents a 1,602.1% increase from the current price of $7.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is HCW Biologics Inc.'s business model?
The company leverages proprietary platform technologies to develop biologics that target senescent cells, which are implicated in chronic diseases. HCW Biologics generates revenue through the discovery and development of innovative therapies that address significant healthcare needs, particularly in oncology and regenerative medicine.
What is the highest forecasted price for HCWB HCW Biologics Inc.?
The highest price target for HCWB is $120.00 from at , which represents a 1,602.1% increase from the current price of $7.05.
What is the lowest forecasted price for HCWB HCW Biologics Inc.?
The lowest price target for HCWB is $120.00 from at , which represents a 1,602.1% increase from the current price of $7.05.
What is the overall HCWB consensus from analysts for HCW Biologics Inc.?
The overall analyst consensus for HCWB is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $120.00.
How accurate are HCWB stock price projections?
Stock price projections, including those for HCW Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.